SlideShare a Scribd company logo
1 of 21
Download to read offline
1
PRESERVING LIFECYCLES
PRESERVING
LIFECYCLES:
Renewing Existing Plant
Protection Active Substances
2
PRESERVING LIFECYCLES
Introduction	 3
Current Agrochemicals Market Backdrop	 3
Active Substances Review and Re-Approval Regulation	 4
Steps to Achieve Successful AS Renewal	 11
Summary	 15
References	 16
Terminology	 17
CONTENTS
3
PRESERVING LIFECYCLES
With the rise in the use of such
products came increasing concerns
about their effect on health and the
environment. In the USA, specific
regulation of such chemicals first
appeared in the early 1900s, but it was
not until 1970 that the Environmental
Protection Agency (EPA) was
created, with the remit of protecting
the environment, and the health of
humans and other animals. In Europe,
the European Council (EC) issued its
first directive on pesticide residues in
1976, with extensive regulatory activity
beginning in the early 1990s.
We have been using
chemicals to protect
plants from pests and
diseases since 2,500 BC,
when, as records show,
ancient Sumarians used
sulfur to control mites/
insects; however, it was
really towards the end
of the 19th century that
the industrial usage of
inorganic products and
those derived naturally,
such as pyrethrum,
became common
and widespread.1
In 2017, the regulation that governs
the marketing, sale and use of plant
protection products (PPPs) is just
a fact of life and a standard part of
international agrochemical business.
However, the standards imposed by
regulation are constantly evolving as
our scientific insight and knowledge
increases, so active substances (ASs)
and PPPs previously approved as safe
may need to be reviewed against
new standards.
INTRODUCTION
This informational e-book is
designed to examine how existing
ASs are managed through the
current regulatory renewal
systems in the EU and USA.
4
PRESERVING LIFECYCLES
The annual growth
rate for PPPs (2017
to 2022) is estimated
to be 5.79%.2
CURRENT AGROCHEMICALS MARKET BACKDROP
On a broader political front, the
EU is reviewing its current legislation
through the REFIT program, while
in the USA, President Trump’s
reforms to the EPA may also impact
the regulatory environment.
Challenges and opportunities
also exist in the plant protection
market. Important patent expiries
are expected in the coming year,
and merger and acquisition activity
among agrochemical companies is
changing the competitive landscape;
for example, the merger of Dow
Chemical and DuPont has required
divestment of certain parts of each
company’s business, with the
USA requiring DuPont to shed
its herbicide/insecticide business
(acquired by FMC), and Brazil’s CADE
(Administrative Council for Economic
Defense) requiring Dow to divest part
of its corn hybrid seed business, which
it has sold to China’s Citic Agri Fund.3
Against this backdrop, the history,
knowledge and insight about
established active substances could
get ‘lost’, and such changes may pose
risks for reauthorization of PPPs.
The growth in the market will mainly
be driven by increasing food demand
from a growing global population
and the need to increase crop yields.
5
PRESERVING LIFECYCLES
In major global markets, regulatory
approval usually constitutes two parts:
first, approval of the so-called AS
or technical-grade active ingredient
(TGAI) and, second, approval of the
actual end-use or formulated PPPs
containing one or more approved
ASs. Approvals are usually time limited;
therefore, both the ASs and the PPPs
must be reapproved and reauthorized
once approval lapses.
The most sophisticated and developed programs for review
and re-approval of ASs and PPPs are in the major US
and European markets. This e-book focuses on the review
programs in use by those regions, while recognizing that
other important markets, such those in Japan, Australia
and New Zealand, Canada and Brazil, have well-developed
crop protection legislation to ensure safety to humans
and the environment when PPPs are authorized for use
in their territories.
US REGULATION OF ASs AND PPPs
The EPA Office of Pesticide Programs handles most
of the regulatory issues pertaining to PPPs, using
authority from the Federal Insecticide, Fungicide,
and Rodenticide Act (FIFRA). All PPPs being sold
or distributed in the USA must be registered with
the EPA. The EPA evaluates the PPP’s proposed usage
and labeling, to ensure it will not have unreasonable
adverse effects on humans or the environment.
AS REVIEW AND RE-APPROVAL REGULATION
Both the ASs and the PPPs must be reapproved
and reauthorized once approval lapses.
6
PRESERVING LIFECYCLES
The EPA reviews each registered AS
at least every 15 years to determine if
it meets current FIFRA standards for
registration. ASs registered before 1984
have been re-evaluated initially under
the re-registration program. These ASs
are also subject to registration review.4
REGISTRATION REVIEW PROGRAM
The EPA plans to review all ASs registered on or before
1st October 2007 by 1st October 2022. Schedules of reviews
and consultations before reviews are published and
updated annually. New ASs will be added to the schedules
as they approach 15 years’ post-registration. The EPA
is planning to start 70 or more new registration reviews
in 2017.4
Reviews are structured into review ‘cases’ that group ASs
together for a number of possible reasons, including their
chemical class or structure, mode of action or use.
7
PRESERVING LIFECYCLES
A detailed description of the process and
procedures can be found on the EPA website
under registration review procedures.
FIGURE 1: EPA REGISTRATION
REVIEW AS OF JANUARY 1, 20164
165COMPLETED
interim or
final decisions
~724registration review cases
>550inACTIV
E
registration
review
>630OPENregistr
ation review cases
~1,140
active
ingredients
8
PRESERVING LIFECYCLES
FIGURE 2: THE EPA REGISTRATION REVIEW PROCESS4
DOCKET
OPENING
FOCUS
MEETING
REGISTRATION
REVIEW
DECISION
CASE
DEVELOPMENT
Summarizes the
pesticide information
and the review plan.
Typically initiated with
affected registrants and
other stakeholders early
in the process.
EPA assesses changes
in law/regulation
since last review.
EPA issues a draft
decision with a 60-day
comment period.
It contains:
Acts about the pesticide
and its use
The anticipated risk
assessment and data needs
An estimated review timeline.
The preliminary workplan
undergoes public consultation
for 60 days after which a final
workplan is published.
If new assessment is needed,
data gaps are identified and
registrants asked for data
call-in (DCI).
Risk assessment or risk/benefit
analysis is undertaken if needed.
The public and regulatory
partners are consulted.
After this point, a final decision
is issued on which the registrant
must act.
In some situations, interim
decisions are issued before
the final decision. This may
require risk mitigation
measures, call for new data,
and outline schedules for
subsequent data submission
and review.
The focus is to identify
information needs and provide
an opportunity to address areas
of uncertainty affecting the
risk assessment and risk
management decisions.
Although not mandatory,
they are recommended.
9
PRESERVING LIFECYCLES
The legislation concerning
the placing of PPPs on the
European single market
is included in Regulation
(EC) No. 1107/2009,
with the specific data
requirements for ASs
and PPPs contained
in Regulations (EU)
No. 283/2013 and
No. 284/2013.
The authorization of ASs generally
expires after ten years. To enable
continued marketing and sales
of PPPs, a renewal of authorization
of the ASs must be sought.
This renewal procedure is covered
by Commission implementing
Regulation (EU) No. 844/2012.5
and is a European-level process.
Article 43 of Regulation (EC)
No. 1107/2009 also provides the
framework for the renewal of PPPs
following the re-approval of an AS.
This process is further elaborated on
in a European Commission guidance
document.6 The renewal of PPPs is
the responsibility of the individual
European Member States.
EUROPEAN REGULATION
RENEWAL PROGRAMS
The programs for renewal of
ASs in the EU are known as
Annex I Renewal (AIR) programs.
ASs are assigned to a program, group
and/or batch, based on their expiration
dates and level of priority, in order
to manage and spread the workload
of the renewal process. The AIR
programs also assign each AS a
‘Rapporteur Member State’ (RMS)
to undertake the task of evaluating
the renewal application.
The legislation concerning the placing
of PPPs on the European single
market is included in Regulation
(EC) No. 1107/2009
10
PRESERVING LIFECYCLES
THERE ARE FOUR AIR PROGRAMS, AS OUTLINED IN TABLE 1.
TABLE 1: THE AIR PR GRAMS, AS OF FEBRUARY 2017
AS EXPIRY DATES NUMBER OF ASs REGULATION NOTES
AIR1 7 (pilot project) EC NO. 737/2007 All substances were renewed for expiry
on December 31, 2021, so they are due for
second renewal under AIR4 and as such,
are due for second renewal under AIR
AIR2 2011–2012 31 EU NO. 1141/2010 29 renewal dossiers were submitted.
It was necessary to extend the expiry
dates for 23 of the ASs
AIR3 January 1, 2013 –
December 31, 2018
150 EU NO. 844/2012
EU NO. 1107/2009
Applications split into batches,
with extensions for some to allow
for sufficient time for dossier preparation
by companies and/or balance workload
in reviewing States
AIR4 January 1, 2019 –
December 31, 2021
214 EU NO. 844/2012
EU NO. 1107/2009
Prioritized into four groups
(SANTE-2016-10616),
Details of the latest updates for renewal programs,
AIR3 and AIR4, can be found on the EC website
11
PRESERVING LIFECYCLES
For the current AIR4 substances,
applicants must apply for renewal
three years before the expiry date
of an approved AS.
Article 17 of Regulation 1107/2009
allows for extensions to the expiry
dates of ASs, where it would not
be possible to take a decision before
the current expiry date, for reasons
beyond the control of the applicant.
THE MAIN REASONS THESE
EXTENSIONS ARE REQUIRED ARE:
▶▶ Delays in assessment
▶▶ Delays in decision-making –
this is true for highly complex cases
▶▶ Facilitation of the review through the Member States
by balancing capacity – this is the case for AIR4.
TIMELINES AND EXTENSIONS
12
PRESERVING LIFECYCLES
FIGURE 3: THE AIR RENEWAL PROCESS7
APPLICATION
(36 months
before expiry)
SUBMISSION
(30 months
before expiry)
RAR
EVALUATION
(RAR issued
12 months post
submission)
PEER
REVIEW
(Review
8 1/2 – 11
months)
RENEWAL
DECISION
(~9 months
duration)
APPLICATION
REVIEW
Registrants submit
an application containing
limited information
to indicate their intent
of submitting a dossier
to pursue active
substance renewal.
RMS conducts
admissibility check.
Registrant must
respond within 14 days
to calls for missing
information.
Registrants create
and submit
a renewal dossier.
For most ASs, the dossier
must be submitted 6
months post-application.
For AIR4, some groups’
expiry dates have been
extended by 1 to 3 years
to allow more time
for dossier submission.
RMS conducts an initial
review check; registrants
must respond to any
data requests within
14 days.
A draft Renewal
Assessment Report (RAR)
is issued 12 months
after dossier submission.
Requests for additional
information may be made.
The RAR is passed to the
European Food Safety
Authority for publication
and consultation.
The final decision is made
by a vote of the Standing
Committee on the Food
Chain and Animal Health.
Renewal is officially adopted
by the Commission and
the results are published.
13
PRESERVING LIFECYCLES
In the final section of this
e-book, we will provide
some practical advice
to help companies tackle
the renewal process.
FORM A TASKFORCE
OR CONSORTIUM
A major difference between the
application for marketing authorization
of a new AS and that for renewal of
an existing substance is that renewals
are likely to involve more than one
applicant and take the form of a
joint submission. In fact, there is an
expectation that stakeholders with an
interest in the AS will reach agreement
to cooperate in the re-approval process
and submit a joint dossier.
For joint submissions to work
efficiently, it is important to establish
a task force or consortium of all
companies that have an interest in an
AS used in specific PPPs. With many
older chemicals out of patent, the list
of interested companies could be large.
By establishing a consortium, the
division of the costs for dossier creation
and submission can be shared within
a clear legal framework. Once renewal
is gained, all parties share the data,
which can be used for the renewal
of individual PPP registrations.
STEPS TO ACHIEVE SUCCESSFUL ‘AS’ RENEWAL
PLAN AHEAD
AND START EARLY
From experience, we know that
you need to start well before the
application date for an AS renewal.
In the EU, where applications are
required three years before the expiry
date, however it is recommended to
start the process at least two years
before that – that is, five years before
expiry. This gives sufficient time for
the following important activities:
▶▶ Assess data gaps: it is essential
to review the data available for
the AS against the current data
requirements and guidance, to
identify what data are missing or
suboptimal. Past experience and
learning from substances that have
already been, or are being, evaluated
as part of earlier AIR submissions
can also be taken into account.
14
PRESERVING LIFECYCLES
▶▶ Identify a costed plan for addressing
gaps in data: once data gaps are
established, the next step is creating
a plan to address them. This plan
should identify what studies could
be defended and what new studies
may need to be carried out. The
challenge when consortia reach
this stage is balancing the
expenditure of new studies against
the overall return from the AS.
Having both regulatory and
scientific expertise under one roof
enhances decision-making and
prioritization at this stage.
▶▶ Conduct studies: by starting
two years before the application
deadline for renewal, it is possible
to conduct two seasons of field
studies if required.
▶▶ Organize a pre-submission
meeting with the RMS: this is the
opportunity to have an open and
frank discussion with the RMS
about your AS, and the plans and
strategy for renewal. It is important
that particular areas of concern are
discussed. Experience has shown
these meetings are invaluable
for both parties, with many
questions answered.
▶▶ Prepare and submit the renewal
application and updating statement:
this should include a reference list
detailing the new studies that are
intended to be submitted in the
supplementary renewal dossier.
▶▶ Prepare and submit the
supplementary renewal dossier:
the dossier should be written up
to the appropriate standards and
following the templates required.
It is important to build a case
that will resonate with regulatory
reviewers, anticipating and
answering their concerns.
The dossier is prepared and
submitted in CADDY format.
▶▶ Respond to RMS questions during
their evaluation: the time for
preparing responses is usually
limited, and it is important to
have a clear understanding what
is being asked, so seek clarification
if necessary. Try to answer as fully
as possible.
▶▶ Comment on RAR: it is important
to be prepared to respond to the
RARs when they are issued a year
after dossier submission. Review
them objectively, and be prepared
to defend studies and provide
comprehensive answers to
any questions.
15
PRESERVING LIFECYCLES
Application
(36 months before expiry)
RAR
(12 months after
submission)
Submission
(30 months before expiry)
-5 -4 -3 -2 -1 EXPIRY
PROPOSED REGISTRANT ACTIVITY TIMEFRAME
EU REGULATORY RENEWAL TIMEFRAME
Renewal decision
Pre-submission meeting
(sometime before application)
Defend
dossier and
respond
to RAR
Data gap
analysis
Prepareand
submitdossier
Study
plan
Conduct studies –
allowing 2 seasons of field studies
FIGURE 4: THE ROUTE THROUGH AS RENEWAL
16
PRESERVING LIFECYCLES
Given the complexity of managing
these long-term, regulatory renewals
and study programs, it can be of great
added value to work with a partner
who has experience in all the stages
of the process.
WORK WITH AN EXPERIENCED PARTNER
TRUSTED PARTNERS CAN PROVIDE
NUMEROUS ADVANTAGES THROUGHOUT
THE RENEWAL PROCESS, INCLUDING:
▶▶ Wide experience covering multiple AS chemistries
and activities
▶▶ A consultancy team with a background in industry,
authorities, Contract Research Organizations (CROs)
and other consulting companies
▶▶ Thorough understanding of the crop protection market
▶▶ Strategic focus and industry perspective
▶▶ Experience and proven track record
▶▶ Flexible approach and close partnership
▶▶ Detailed planning and project management
▶▶ Timely communication
It is important to remember that once the AS has been
re-authorized, the process of product renewal begins,
following the procedures laid down in Article 43.
17
PRESERVING LIFECYCLES
▶▶ Literature review: A comprehensive literature
search, that meets the criteria in the EFSA Guidance
(is required.8-11
A tiered approach is taken in order
to identify those papers that are both relevant
and reliable, and therefore merit inclusion and
consideration of the results in the renewal dossier.
▶▶ Harmonized classification and labeling (CLH) of
ASs is the responsibility of the European Chemicals
Agency (ECHA). This requires preparation of dossiers
(including IUCLID technical dossiers) for CLH under
Regulation (EC) No. 1272/2008 (CLP Regulation),
preparation of expert statements on technical
and scientific issues regarding toxicity of ASs
and supporting clients at ECHA risk assessment
committee meetings.
OTHER IMPORTANT ELEMENTS OF EU ‘AS’ REVIEW
▶▶ Maximum residue levels (MRLs): It is important to
have appropriate MRLs (and/or import tolerances [ITs])
in place for all uses, not just the representative uses
included in the renewal dossier. MRL application and
setting is covered by Regulation (EC) No. 396/2005.10
18
PRESERVING LIFECYCLES
The renewal process
in the EU for existing
ASs requires advance
planning and careful,
attentive management.
SUMMARY
FOUR KEY PIECES
OF ADVICE ARE:
▶▶ Start early and plan ahead: do
not leave planning for your renewal
to the last minute. You need to
start planning at least five years
before the AS expiry date to give
you time to establish, if necessary,
a task force or consortium and
agree your strategy, budget
working practices and study
program for the renewal process.
▶▶ Communicate clearly and work
collaboratively with others: effective
working partnerships with other
stakeholders, such as task force
members, consultants and CROs,
requires good communication
and clear agreement of roles
and responsibilities. Engage with
the renewing authority early to
establish possible issues and scope.
▶▶ Be bold but realistic: review the
data for your AS and characterize
data gaps comprehensively;
however, do not be afraid to look
at your existing studies and plan
a robust defense of them, while
always having a contingency.
▶▶ Remember this is an ongoing
process: renewal of approval is
only a step towards meeting your
commercial objectives, and the
next stage of renewal of products,
introduction of new products
and extensions of use of existing
products are just as important
and require careful planning
and management.
19
PRESERVING LIFECYCLES
1	
Aspinal A. Pesticide usage in the United
	 States: Trends During the 20th Century.
	 Center for Integrated Pest Management.
	 CIPM Technical Bulletin 2003; 105.
2	
Mordor Intelligence. Crop protection
	 chemicals (Pesticides) Market - Global
	 Industry Growth, Trends and Forecasts
	 (2017 - 2022). Published February 2017.
	www.mordorintelligence.com/industry-
	reports/global-crop-protection-chemicals-
	pesticides-market-industry
3	
Reuters. BRIEF-Dow to divest portion
	 of its corn hybrid seed business in Brazil
	 to CITIC Agri Fund for $1.1 bln. July 11,
	 2017 http://uk.reuters.com/article/
	brief-dow-to-divest-portion-of-its-corn-
	idUKASA09WQR
4	
United States Environmental Protection
	 Agency. Registration Review Process.
	 www.epa.gov/pesticide-reevaluation/
	registration-review-process
REFERENCES
5	
EFSA. Applications helpdesk – Renewal
	 of approval under AIR programme:
	 application procedure. www.efsa.europa.
	 eu/sites/default/files/applications/
	RenewalApprovalActSubPro.pdf
6	
European Commission.
	 SANCO/2010/13170 rev. 14.
	 Guidance Document on the Renewal
	 of Authorizations according to Article 43
	 of Regulation (EC) No 1107/2009. 2016. 	
	 October 7, 2016. https://ec.europa.eu/
	 food/sites/food/files/plant/
	docs/pesticides_aas_guidance_
	renewal_1107-2009.pdf
7	
1107 Vademecum, Fourth Edition,
	 Pappas & Associates, Brussels, 2017
8	
EFSA. Submission of scientific peer-
	 reviewed open literature for the approval
	 of pesticide active substances under
	 Regulation (EC) No 1107/2009. EFSA
	 Journal 2011; 9(2): 2092. https://efsa.
	onlinelibrary.wiley.com/doi/epdf/
	10.2903/j.efsa.2011.2092
9	
European Union. Regulation (EC) No.
	 1107/2009 of the European Parliament
	 and of the Council of 21 October 2009
	 concerning the placing of plant protection
	 products on the market and repealing
	 Council Directive 79/117/EEC
	 and 91/414/EEC. Official Journal
	 of the European Union L 309,
	 November 24, 2009. https://eur-lex.
	europa.eu/legal-content/EN/TXT/
	PDF/?uri=OJ:L:2009:309:FULL&from=EN
10	
European Parliament, Council of the
	 European Union. Regulation (EC) No.
	 396/2005 of the European Parliament
	 and of the Council of 23 February 2005 on
	 maximum residue levels of pesticides
	 in or on food and feed of plant and
	 animal origin and amending Council
	 Directive 91/414/ EEC. Official
	 Journal of the European Union L
	 70, March 16, 2005. https://eur-lex.
	europa.eu/legal-content/EN/TXT/
	PDF/?uri=OJ:L:2005:070:FULL&from=EN
11	
European Commission. Renewal of
	approval. https://ec.europa.eu/food/
	plant/pesticides/approval_active_
	substances/approval_renewal_en
20
PRESERVING LIFECYCLES
AIR	 Annex I Renewal
AS	 Active substance
CLH	 Harmonized classification and labeling
CLP	 Classification, Labeling and Packaging
CRO	 Contract research organization
DCI	 Data call-in
EFSA	 European Food Safety Authority
EPA	 Environment Protection Agency
EU	 European Union
FIFRA	 Federal Insecticide, Fungicide,
	 and Rodenticide Act
TERMINOLOGY
IT	 Import tolerance
MRL	 Maximum residue level
PPP	 Plant protection product – a term often used
	 interchangeably with the term pesticide; 		
	 however, pesticide is broader and also covers 		
	 non-plant or crop use (for example, biocides)
RAR	 Renewal Assessment Report
RMS	 Rapporteur Member State – the member
	 state of the EU that acts as the lead reviewer
	 of renewal dossiers
TGAI	 Technical-grade active ingredient
21
PRESERVING LIFECYCLES
Learn more about our
crop protection solutions at
www.covance.com/crop-protection
Covance is the drug, medical device and diagnostics business
segment of LabCorp, a leading global life sciences company.
COVANCE is a registered trademark and the marketing name
for Covance Inc. and its subsidiaries around the world.
The Americas +1.888.COVANCE
(+1.888.268.2623) +1.609.452.4440
Europe/Africa +00.800.2682.2682 +44.1423.500888
Asia Pacific +800.6568.3000 +65.6.5686588
© Copyright 2019 Covance Inc.
EBKCPC001-0819

More Related Content

What's hot

pharmaceutical policy - 2002
 pharmaceutical policy - 2002 pharmaceutical policy - 2002
pharmaceutical policy - 2002Suvarta Maru
 
Indian Pharma DPCO 2013 List
Indian Pharma DPCO 2013 ListIndian Pharma DPCO 2013 List
Indian Pharma DPCO 2013 ListAnup Soans
 
Essential commodity act 1955
Essential commodity act 1955Essential commodity act 1955
Essential commodity act 1955Divya Chhabra
 
Essential commodities act, 1955
Essential commodities act, 1955Essential commodities act, 1955
Essential commodities act, 1955amitgurus
 
National pharmaceutical pricing athourity (nppa)
National pharmaceutical pricing athourity (nppa)National pharmaceutical pricing athourity (nppa)
National pharmaceutical pricing athourity (nppa)bdvfgbdhg
 
The drugs (prices control) order,
The drugs (prices control) order,The drugs (prices control) order,
The drugs (prices control) order,Sharon Vijayanand
 
FSSA 2011kiran b k
FSSA 2011kiran b kFSSA 2011kiran b k
FSSA 2011kiran b kPrajwal N R
 
Drug price control order 1995
Drug price control order 1995Drug price control order 1995
Drug price control order 1995Rajveer Bhaskar
 
Priscription drug user free act......sn
Priscription drug user free act......snPriscription drug user free act......sn
Priscription drug user free act......snbdvfgbdhg
 
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015 Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015 Anup Soans
 
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFR
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFRYuvraj Regmi on Hatch-Waxman Act and Amendments and CFR
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFRYUVRAJ REGMI
 
Drug price control order 2013
Drug price control order 2013Drug price control order 2013
Drug price control order 2013Tushar Morankar
 
Hazardous Substances Laws and Regulations
Hazardous Substances Laws and RegulationsHazardous Substances Laws and Regulations
Hazardous Substances Laws and Regulationsbbryner
 
Essential commodities act, 1955
Essential commodities act, 1955Essential commodities act, 1955
Essential commodities act, 1955Megha Roy
 
fsma proposed rule on intentional adulteration
fsma proposed rule on intentional adulterationfsma proposed rule on intentional adulteration
fsma proposed rule on intentional adulterationifmaworld
 

What's hot (19)

pharmaceutical policy - 2002
 pharmaceutical policy - 2002 pharmaceutical policy - 2002
pharmaceutical policy - 2002
 
Drug pricing policy india
Drug pricing policy indiaDrug pricing policy india
Drug pricing policy india
 
Indian Pharma DPCO 2013 List
Indian Pharma DPCO 2013 ListIndian Pharma DPCO 2013 List
Indian Pharma DPCO 2013 List
 
Essential commodity act 1955
Essential commodity act 1955Essential commodity act 1955
Essential commodity act 1955
 
Essential commodities act, 1955
Essential commodities act, 1955Essential commodities act, 1955
Essential commodities act, 1955
 
National pharmaceutical pricing athourity (nppa)
National pharmaceutical pricing athourity (nppa)National pharmaceutical pricing athourity (nppa)
National pharmaceutical pricing athourity (nppa)
 
The drugs (prices control) order,
The drugs (prices control) order,The drugs (prices control) order,
The drugs (prices control) order,
 
Ska
SkaSka
Ska
 
FSSA 2011kiran b k
FSSA 2011kiran b kFSSA 2011kiran b k
FSSA 2011kiran b k
 
Drug price control order 1995
Drug price control order 1995Drug price control order 1995
Drug price control order 1995
 
Priscription drug user free act......sn
Priscription drug user free act......snPriscription drug user free act......sn
Priscription drug user free act......sn
 
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015 Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015
 
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFR
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFRYuvraj Regmi on Hatch-Waxman Act and Amendments and CFR
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFR
 
Essential commodities
Essential commoditiesEssential commodities
Essential commodities
 
Drug price
Drug priceDrug price
Drug price
 
Drug price control order 2013
Drug price control order 2013Drug price control order 2013
Drug price control order 2013
 
Hazardous Substances Laws and Regulations
Hazardous Substances Laws and RegulationsHazardous Substances Laws and Regulations
Hazardous Substances Laws and Regulations
 
Essential commodities act, 1955
Essential commodities act, 1955Essential commodities act, 1955
Essential commodities act, 1955
 
fsma proposed rule on intentional adulteration
fsma proposed rule on intentional adulterationfsma proposed rule on intentional adulteration
fsma proposed rule on intentional adulteration
 

Similar to Renewing Existing Plant Protection Active Substances

Regulatory aspect of pharamacutical packging
Regulatory aspect of pharamacutical packgingRegulatory aspect of pharamacutical packging
Regulatory aspect of pharamacutical packgingvineet gupta
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical DocumentDr Sukanta sen
 
A report outlining the differences in the Biosimilar regulatory market betwee...
A report outlining the differences in the Biosimilar regulatory market betwee...A report outlining the differences in the Biosimilar regulatory market betwee...
A report outlining the differences in the Biosimilar regulatory market betwee...MalavikaSankararaman
 
Respiratory devices market
Respiratory devices marketRespiratory devices market
Respiratory devices marketAkshay Shinde
 
Eu Regulatory & Quality Environment- Abhishek Raval
Eu Regulatory & Quality Environment- Abhishek RavalEu Regulatory & Quality Environment- Abhishek Raval
Eu Regulatory & Quality Environment- Abhishek RavalAbhishekRaval16
 
US Toxic Substances Control Act (TSCA) Reform
US Toxic Substances Control Act (TSCA) ReformUS Toxic Substances Control Act (TSCA) Reform
US Toxic Substances Control Act (TSCA) ReformCovance
 
Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...Diane Hatziioanou
 
CLP Regulations eBook
CLP Regulations eBookCLP Regulations eBook
CLP Regulations eBookArpal Group
 
CTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory AffairsCTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory AffairsDipesh Gosavi
 
SPCs as Targets for Litigation: C5 Presentation 18 February 2009
SPCs as Targets for Litigation: C5 Presentation 18 February 2009SPCs as Targets for Litigation: C5 Presentation 18 February 2009
SPCs as Targets for Litigation: C5 Presentation 18 February 2009Dr Duncan Curley
 
Phụ lục 3. Các chế định trong việc đánh giá sản phẩm sinh học trị liệu có ngu...
Phụ lục 3. Các chế định trong việc đánh giá sản phẩm sinh học trị liệu có ngu...Phụ lục 3. Các chế định trong việc đánh giá sản phẩm sinh học trị liệu có ngu...
Phụ lục 3. Các chế định trong việc đánh giá sản phẩm sinh học trị liệu có ngu...Công ty Cổ phần Tư vấn Thiết kế GMP EU
 
Waste management responsibilities for producers and importers in russia
Waste management responsibilities for producers and importers in russiaWaste management responsibilities for producers and importers in russia
Waste management responsibilities for producers and importers in russiaLidings Law Firm
 
CLP Regulations eBook
CLP Regulations eBookCLP Regulations eBook
CLP Regulations eBookArpal Group
 
Prescription drug user fee act and its influence on review time and budget
Prescription drug user fee act and its influence on review time and budgetPrescription drug user fee act and its influence on review time and budget
Prescription drug user fee act and its influence on review time and budgetSriramNagarajan17
 
New Product Registration - Key Considerations when Registering New Products
New Product Registration - Key Considerations when Registering New ProductsNew Product Registration - Key Considerations when Registering New Products
New Product Registration - Key Considerations when Registering New ProductsCovance
 
Pharmaceutical Patenting in India.
Pharmaceutical Patenting in India.Pharmaceutical Patenting in India.
Pharmaceutical Patenting in India.TanyaJain131
 
Extended producer responsibility (epr)
Extended producer responsibility (epr)Extended producer responsibility (epr)
Extended producer responsibility (epr)jackass18
 

Similar to Renewing Existing Plant Protection Active Substances (20)

Regulatory aspect of pharamacutical packging
Regulatory aspect of pharamacutical packgingRegulatory aspect of pharamacutical packging
Regulatory aspect of pharamacutical packging
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
 
EU Pesticides Consultation
EU Pesticides ConsultationEU Pesticides Consultation
EU Pesticides Consultation
 
A report outlining the differences in the Biosimilar regulatory market betwee...
A report outlining the differences in the Biosimilar regulatory market betwee...A report outlining the differences in the Biosimilar regulatory market betwee...
A report outlining the differences in the Biosimilar regulatory market betwee...
 
Respiratory devices market
Respiratory devices marketRespiratory devices market
Respiratory devices market
 
Eu Regulatory & Quality Environment- Abhishek Raval
Eu Regulatory & Quality Environment- Abhishek RavalEu Regulatory & Quality Environment- Abhishek Raval
Eu Regulatory & Quality Environment- Abhishek Raval
 
US Toxic Substances Control Act (TSCA) Reform
US Toxic Substances Control Act (TSCA) ReformUS Toxic Substances Control Act (TSCA) Reform
US Toxic Substances Control Act (TSCA) Reform
 
Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...
 
CLP Regulations eBook
CLP Regulations eBookCLP Regulations eBook
CLP Regulations eBook
 
General Biocides Booklet
General Biocides BookletGeneral Biocides Booklet
General Biocides Booklet
 
CTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory AffairsCTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory Affairs
 
SPCs as Targets for Litigation: C5 Presentation 18 February 2009
SPCs as Targets for Litigation: C5 Presentation 18 February 2009SPCs as Targets for Litigation: C5 Presentation 18 February 2009
SPCs as Targets for Litigation: C5 Presentation 18 February 2009
 
Phụ lục 3. Các chế định trong việc đánh giá sản phẩm sinh học trị liệu có ngu...
Phụ lục 3. Các chế định trong việc đánh giá sản phẩm sinh học trị liệu có ngu...Phụ lục 3. Các chế định trong việc đánh giá sản phẩm sinh học trị liệu có ngu...
Phụ lục 3. Các chế định trong việc đánh giá sản phẩm sinh học trị liệu có ngu...
 
Waste management responsibilities for producers and importers in russia
Waste management responsibilities for producers and importers in russiaWaste management responsibilities for producers and importers in russia
Waste management responsibilities for producers and importers in russia
 
ANDA, IMPD & IB
ANDA, IMPD & IBANDA, IMPD & IB
ANDA, IMPD & IB
 
CLP Regulations eBook
CLP Regulations eBookCLP Regulations eBook
CLP Regulations eBook
 
Prescription drug user fee act and its influence on review time and budget
Prescription drug user fee act and its influence on review time and budgetPrescription drug user fee act and its influence on review time and budget
Prescription drug user fee act and its influence on review time and budget
 
New Product Registration - Key Considerations when Registering New Products
New Product Registration - Key Considerations when Registering New ProductsNew Product Registration - Key Considerations when Registering New Products
New Product Registration - Key Considerations when Registering New Products
 
Pharmaceutical Patenting in India.
Pharmaceutical Patenting in India.Pharmaceutical Patenting in India.
Pharmaceutical Patenting in India.
 
Extended producer responsibility (epr)
Extended producer responsibility (epr)Extended producer responsibility (epr)
Extended producer responsibility (epr)
 

More from Covance

Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...Covance
 
Genomics Solutions - Single Target to Whole Genome Analysis
Genomics Solutions - Single Target to Whole Genome AnalysisGenomics Solutions - Single Target to Whole Genome Analysis
Genomics Solutions - Single Target to Whole Genome AnalysisCovance
 
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...Covance
 
Pharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsPharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsCovance
 
Cell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCovance
 
Cell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCovance
 
Cell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development SolutionsCell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development SolutionsCovance
 
Inhalation Technology - The Future of Effective Respiratory Treatments
Inhalation Technology - The Future of Effective Respiratory TreatmentsInhalation Technology - The Future of Effective Respiratory Treatments
Inhalation Technology - The Future of Effective Respiratory TreatmentsCovance
 
Covance Laboratory FSPx Solutions
Covance Laboratory FSPx SolutionsCovance Laboratory FSPx Solutions
Covance Laboratory FSPx SolutionsCovance
 
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...Covance
 
Environmental Risk Assessment for Pharmaceutical Drugs
Environmental Risk Assessment for Pharmaceutical DrugsEnvironmental Risk Assessment for Pharmaceutical Drugs
Environmental Risk Assessment for Pharmaceutical DrugsCovance
 
Getting Investigators Onboard: Lab Preferences Make a Difference in Trial Par...
Getting Investigators Onboard: Lab Preferences Make a Difference in Trial Par...Getting Investigators Onboard: Lab Preferences Make a Difference in Trial Par...
Getting Investigators Onboard: Lab Preferences Make a Difference in Trial Par...Covance
 
Putting the Patient First: Launching a Comprehensive Patient-Centric Program
Putting the Patient First: Launching a Comprehensive Patient-Centric ProgramPutting the Patient First: Launching a Comprehensive Patient-Centric Program
Putting the Patient First: Launching a Comprehensive Patient-Centric ProgramCovance
 
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty MarketTop 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty MarketCovance
 
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...Covance
 
Covance Phase IV Solutions Brochure
Covance Phase IV Solutions BrochureCovance Phase IV Solutions Brochure
Covance Phase IV Solutions BrochureCovance
 
Optimizing Each Patient's Product Access Experience
Optimizing Each Patient's Product Access ExperienceOptimizing Each Patient's Product Access Experience
Optimizing Each Patient's Product Access ExperienceCovance
 
Patient Safety Cloud Solution Brochure
Patient Safety Cloud Solution BrochurePatient Safety Cloud Solution Brochure
Patient Safety Cloud Solution BrochureCovance
 
Plant Metabolism Studies: Options for Plant Cultivation
Plant Metabolism Studies: Options for Plant CultivationPlant Metabolism Studies: Options for Plant Cultivation
Plant Metabolism Studies: Options for Plant CultivationCovance
 
Biocide Authorization Timeline
Biocide Authorization TimelineBiocide Authorization Timeline
Biocide Authorization TimelineCovance
 

More from Covance (20)

Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
 
Genomics Solutions - Single Target to Whole Genome Analysis
Genomics Solutions - Single Target to Whole Genome AnalysisGenomics Solutions - Single Target to Whole Genome Analysis
Genomics Solutions - Single Target to Whole Genome Analysis
 
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
 
Pharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsPharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for Biosimilars
 
Cell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval Solutions
 
Cell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise Solutions
 
Cell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development SolutionsCell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development Solutions
 
Inhalation Technology - The Future of Effective Respiratory Treatments
Inhalation Technology - The Future of Effective Respiratory TreatmentsInhalation Technology - The Future of Effective Respiratory Treatments
Inhalation Technology - The Future of Effective Respiratory Treatments
 
Covance Laboratory FSPx Solutions
Covance Laboratory FSPx SolutionsCovance Laboratory FSPx Solutions
Covance Laboratory FSPx Solutions
 
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
 
Environmental Risk Assessment for Pharmaceutical Drugs
Environmental Risk Assessment for Pharmaceutical DrugsEnvironmental Risk Assessment for Pharmaceutical Drugs
Environmental Risk Assessment for Pharmaceutical Drugs
 
Getting Investigators Onboard: Lab Preferences Make a Difference in Trial Par...
Getting Investigators Onboard: Lab Preferences Make a Difference in Trial Par...Getting Investigators Onboard: Lab Preferences Make a Difference in Trial Par...
Getting Investigators Onboard: Lab Preferences Make a Difference in Trial Par...
 
Putting the Patient First: Launching a Comprehensive Patient-Centric Program
Putting the Patient First: Launching a Comprehensive Patient-Centric ProgramPutting the Patient First: Launching a Comprehensive Patient-Centric Program
Putting the Patient First: Launching a Comprehensive Patient-Centric Program
 
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty MarketTop 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
 
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
 
Covance Phase IV Solutions Brochure
Covance Phase IV Solutions BrochureCovance Phase IV Solutions Brochure
Covance Phase IV Solutions Brochure
 
Optimizing Each Patient's Product Access Experience
Optimizing Each Patient's Product Access ExperienceOptimizing Each Patient's Product Access Experience
Optimizing Each Patient's Product Access Experience
 
Patient Safety Cloud Solution Brochure
Patient Safety Cloud Solution BrochurePatient Safety Cloud Solution Brochure
Patient Safety Cloud Solution Brochure
 
Plant Metabolism Studies: Options for Plant Cultivation
Plant Metabolism Studies: Options for Plant CultivationPlant Metabolism Studies: Options for Plant Cultivation
Plant Metabolism Studies: Options for Plant Cultivation
 
Biocide Authorization Timeline
Biocide Authorization TimelineBiocide Authorization Timeline
Biocide Authorization Timeline
 

Recently uploaded

Slide deck for the IPCC Briefing to Latvian Parliamentarians
Slide deck for the IPCC Briefing to Latvian ParliamentariansSlide deck for the IPCC Briefing to Latvian Parliamentarians
Slide deck for the IPCC Briefing to Latvian Parliamentariansipcc-media
 
CCXG global forum, April 2024, Tiza Mafira
CCXG global forum, April 2024,  Tiza MafiraCCXG global forum, April 2024,  Tiza Mafira
CCXG global forum, April 2024, Tiza MafiraOECD Environment
 
Title-Role of forestry in restoration of degraded lands.pptx
Title-Role of forestry in restoration of degraded lands.pptxTitle-Role of forestry in restoration of degraded lands.pptx
Title-Role of forestry in restoration of degraded lands.pptxSagar Chaudhary
 
Broiler SBA.docx for agricultural science csec
Broiler SBA.docx for agricultural science csecBroiler SBA.docx for agricultural science csec
Broiler SBA.docx for agricultural science csecLaceyannWilliams
 
Little Green Ranger ESG Sustainability Report
Little Green Ranger ESG Sustainability ReportLittle Green Ranger ESG Sustainability Report
Little Green Ranger ESG Sustainability ReportKennethOng48
 
CCXG global forum, April 2024, XU Huaqing
CCXG global forum, April 2024,  XU HuaqingCCXG global forum, April 2024,  XU Huaqing
CCXG global forum, April 2024, XU HuaqingOECD Environment
 
CCXG global forum, April 2024, Watcharin Boonyarit
CCXG global forum, April 2024,  Watcharin BoonyaritCCXG global forum, April 2024,  Watcharin Boonyarit
CCXG global forum, April 2024, Watcharin BoonyaritOECD Environment
 
CCXG global forum, April 2024, Jolien Noels
CCXG global forum, April 2024,  Jolien NoelsCCXG global forum, April 2024,  Jolien Noels
CCXG global forum, April 2024, Jolien NoelsOECD Environment
 
CCXG global forum, April 2024, Raphaël Jachnik
CCXG global forum, April 2024, Raphaël JachnikCCXG global forum, April 2024, Raphaël Jachnik
CCXG global forum, April 2024, Raphaël JachnikOECD Environment
 
LCCXG global forum, April 2024, Lydie-Line Paroz
LCCXG global forum, April 2024,  Lydie-Line ParozLCCXG global forum, April 2024,  Lydie-Line Paroz
LCCXG global forum, April 2024, Lydie-Line ParozOECD Environment
 
Science, Technology and Nation Building.pptx
Science, Technology and Nation Building.pptxScience, Technology and Nation Building.pptx
Science, Technology and Nation Building.pptxgrandmarshall132
 
CCXG global forum, April 2024, Adriana Bonilla
CCXG global forum, April 2024,  Adriana BonillaCCXG global forum, April 2024,  Adriana Bonilla
CCXG global forum, April 2024, Adriana BonillaOECD Environment
 
CCXG global forum, April 2024, Amar Bhattacharya
CCXG global forum, April 2024,  Amar BhattacharyaCCXG global forum, April 2024,  Amar Bhattacharya
CCXG global forum, April 2024, Amar BhattacharyaOECD Environment
 
CCXG global forum, April 2024, Manjeet Dhakal
CCXG global forum, April 2024,  Manjeet DhakalCCXG global forum, April 2024,  Manjeet Dhakal
CCXG global forum, April 2024, Manjeet DhakalOECD Environment
 
CCXG global forum, April 2024, Siddharth Singh
CCXG global forum, April 2024, Siddharth SinghCCXG global forum, April 2024, Siddharth Singh
CCXG global forum, April 2024, Siddharth SinghOECD Environment
 
CCXG global forum, April 2024, Sirini Jeudy-Hugo
CCXG global forum, April 2024,  Sirini Jeudy-HugoCCXG global forum, April 2024,  Sirini Jeudy-Hugo
CCXG global forum, April 2024, Sirini Jeudy-HugoOECD Environment
 
CCXG global forum, April 2024, Davi Bonavides
CCXG global forum, April 2024,  Davi BonavidesCCXG global forum, April 2024,  Davi Bonavides
CCXG global forum, April 2024, Davi BonavidesOECD Environment
 
human computer interaction of movie booking system project
human computer interaction of movie booking system projecthuman computer interaction of movie booking system project
human computer interaction of movie booking system project201roopikha
 
CCXG global forum, April 2024, Luca Lo Re
CCXG global forum, April 2024,  Luca Lo ReCCXG global forum, April 2024,  Luca Lo Re
CCXG global forum, April 2024, Luca Lo ReOECD Environment
 

Recently uploaded (20)

Slide deck for the IPCC Briefing to Latvian Parliamentarians
Slide deck for the IPCC Briefing to Latvian ParliamentariansSlide deck for the IPCC Briefing to Latvian Parliamentarians
Slide deck for the IPCC Briefing to Latvian Parliamentarians
 
CCXG global forum, April 2024, Tiza Mafira
CCXG global forum, April 2024,  Tiza MafiraCCXG global forum, April 2024,  Tiza Mafira
CCXG global forum, April 2024, Tiza Mafira
 
Title-Role of forestry in restoration of degraded lands.pptx
Title-Role of forestry in restoration of degraded lands.pptxTitle-Role of forestry in restoration of degraded lands.pptx
Title-Role of forestry in restoration of degraded lands.pptx
 
Broiler SBA.docx for agricultural science csec
Broiler SBA.docx for agricultural science csecBroiler SBA.docx for agricultural science csec
Broiler SBA.docx for agricultural science csec
 
Little Green Ranger ESG Sustainability Report
Little Green Ranger ESG Sustainability ReportLittle Green Ranger ESG Sustainability Report
Little Green Ranger ESG Sustainability Report
 
CCXG global forum, April 2024, XU Huaqing
CCXG global forum, April 2024,  XU HuaqingCCXG global forum, April 2024,  XU Huaqing
CCXG global forum, April 2024, XU Huaqing
 
CCXG global forum, April 2024, Watcharin Boonyarit
CCXG global forum, April 2024,  Watcharin BoonyaritCCXG global forum, April 2024,  Watcharin Boonyarit
CCXG global forum, April 2024, Watcharin Boonyarit
 
CCXG global forum, April 2024, Jolien Noels
CCXG global forum, April 2024,  Jolien NoelsCCXG global forum, April 2024,  Jolien Noels
CCXG global forum, April 2024, Jolien Noels
 
CCXG global forum, April 2024, Raphaël Jachnik
CCXG global forum, April 2024, Raphaël JachnikCCXG global forum, April 2024, Raphaël Jachnik
CCXG global forum, April 2024, Raphaël Jachnik
 
LCCXG global forum, April 2024, Lydie-Line Paroz
LCCXG global forum, April 2024,  Lydie-Line ParozLCCXG global forum, April 2024,  Lydie-Line Paroz
LCCXG global forum, April 2024, Lydie-Line Paroz
 
Science, Technology and Nation Building.pptx
Science, Technology and Nation Building.pptxScience, Technology and Nation Building.pptx
Science, Technology and Nation Building.pptx
 
CCXG global forum, April 2024, Adriana Bonilla
CCXG global forum, April 2024,  Adriana BonillaCCXG global forum, April 2024,  Adriana Bonilla
CCXG global forum, April 2024, Adriana Bonilla
 
CCXG global forum, April 2024, Amar Bhattacharya
CCXG global forum, April 2024,  Amar BhattacharyaCCXG global forum, April 2024,  Amar Bhattacharya
CCXG global forum, April 2024, Amar Bhattacharya
 
CCXG global forum, April 2024, Manjeet Dhakal
CCXG global forum, April 2024,  Manjeet DhakalCCXG global forum, April 2024,  Manjeet Dhakal
CCXG global forum, April 2024, Manjeet Dhakal
 
CCXG global forum, April 2024, Siddharth Singh
CCXG global forum, April 2024, Siddharth SinghCCXG global forum, April 2024, Siddharth Singh
CCXG global forum, April 2024, Siddharth Singh
 
CCXG global forum, April 2024, Sirini Jeudy-Hugo
CCXG global forum, April 2024,  Sirini Jeudy-HugoCCXG global forum, April 2024,  Sirini Jeudy-Hugo
CCXG global forum, April 2024, Sirini Jeudy-Hugo
 
CCXG global forum, April 2024, Davi Bonavides
CCXG global forum, April 2024,  Davi BonavidesCCXG global forum, April 2024,  Davi Bonavides
CCXG global forum, April 2024, Davi Bonavides
 
human computer interaction of movie booking system project
human computer interaction of movie booking system projecthuman computer interaction of movie booking system project
human computer interaction of movie booking system project
 
Health Facility Electrification: State of Play
Health Facility Electrification: State of PlayHealth Facility Electrification: State of Play
Health Facility Electrification: State of Play
 
CCXG global forum, April 2024, Luca Lo Re
CCXG global forum, April 2024,  Luca Lo ReCCXG global forum, April 2024,  Luca Lo Re
CCXG global forum, April 2024, Luca Lo Re
 

Renewing Existing Plant Protection Active Substances

  • 2. 2 PRESERVING LIFECYCLES Introduction 3 Current Agrochemicals Market Backdrop 3 Active Substances Review and Re-Approval Regulation 4 Steps to Achieve Successful AS Renewal 11 Summary 15 References 16 Terminology 17 CONTENTS
  • 3. 3 PRESERVING LIFECYCLES With the rise in the use of such products came increasing concerns about their effect on health and the environment. In the USA, specific regulation of such chemicals first appeared in the early 1900s, but it was not until 1970 that the Environmental Protection Agency (EPA) was created, with the remit of protecting the environment, and the health of humans and other animals. In Europe, the European Council (EC) issued its first directive on pesticide residues in 1976, with extensive regulatory activity beginning in the early 1990s. We have been using chemicals to protect plants from pests and diseases since 2,500 BC, when, as records show, ancient Sumarians used sulfur to control mites/ insects; however, it was really towards the end of the 19th century that the industrial usage of inorganic products and those derived naturally, such as pyrethrum, became common and widespread.1 In 2017, the regulation that governs the marketing, sale and use of plant protection products (PPPs) is just a fact of life and a standard part of international agrochemical business. However, the standards imposed by regulation are constantly evolving as our scientific insight and knowledge increases, so active substances (ASs) and PPPs previously approved as safe may need to be reviewed against new standards. INTRODUCTION This informational e-book is designed to examine how existing ASs are managed through the current regulatory renewal systems in the EU and USA.
  • 4. 4 PRESERVING LIFECYCLES The annual growth rate for PPPs (2017 to 2022) is estimated to be 5.79%.2 CURRENT AGROCHEMICALS MARKET BACKDROP On a broader political front, the EU is reviewing its current legislation through the REFIT program, while in the USA, President Trump’s reforms to the EPA may also impact the regulatory environment. Challenges and opportunities also exist in the plant protection market. Important patent expiries are expected in the coming year, and merger and acquisition activity among agrochemical companies is changing the competitive landscape; for example, the merger of Dow Chemical and DuPont has required divestment of certain parts of each company’s business, with the USA requiring DuPont to shed its herbicide/insecticide business (acquired by FMC), and Brazil’s CADE (Administrative Council for Economic Defense) requiring Dow to divest part of its corn hybrid seed business, which it has sold to China’s Citic Agri Fund.3 Against this backdrop, the history, knowledge and insight about established active substances could get ‘lost’, and such changes may pose risks for reauthorization of PPPs. The growth in the market will mainly be driven by increasing food demand from a growing global population and the need to increase crop yields.
  • 5. 5 PRESERVING LIFECYCLES In major global markets, regulatory approval usually constitutes two parts: first, approval of the so-called AS or technical-grade active ingredient (TGAI) and, second, approval of the actual end-use or formulated PPPs containing one or more approved ASs. Approvals are usually time limited; therefore, both the ASs and the PPPs must be reapproved and reauthorized once approval lapses. The most sophisticated and developed programs for review and re-approval of ASs and PPPs are in the major US and European markets. This e-book focuses on the review programs in use by those regions, while recognizing that other important markets, such those in Japan, Australia and New Zealand, Canada and Brazil, have well-developed crop protection legislation to ensure safety to humans and the environment when PPPs are authorized for use in their territories. US REGULATION OF ASs AND PPPs The EPA Office of Pesticide Programs handles most of the regulatory issues pertaining to PPPs, using authority from the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). All PPPs being sold or distributed in the USA must be registered with the EPA. The EPA evaluates the PPP’s proposed usage and labeling, to ensure it will not have unreasonable adverse effects on humans or the environment. AS REVIEW AND RE-APPROVAL REGULATION Both the ASs and the PPPs must be reapproved and reauthorized once approval lapses.
  • 6. 6 PRESERVING LIFECYCLES The EPA reviews each registered AS at least every 15 years to determine if it meets current FIFRA standards for registration. ASs registered before 1984 have been re-evaluated initially under the re-registration program. These ASs are also subject to registration review.4 REGISTRATION REVIEW PROGRAM The EPA plans to review all ASs registered on or before 1st October 2007 by 1st October 2022. Schedules of reviews and consultations before reviews are published and updated annually. New ASs will be added to the schedules as they approach 15 years’ post-registration. The EPA is planning to start 70 or more new registration reviews in 2017.4 Reviews are structured into review ‘cases’ that group ASs together for a number of possible reasons, including their chemical class or structure, mode of action or use.
  • 7. 7 PRESERVING LIFECYCLES A detailed description of the process and procedures can be found on the EPA website under registration review procedures. FIGURE 1: EPA REGISTRATION REVIEW AS OF JANUARY 1, 20164 165COMPLETED interim or final decisions ~724registration review cases >550inACTIV E registration review >630OPENregistr ation review cases ~1,140 active ingredients
  • 8. 8 PRESERVING LIFECYCLES FIGURE 2: THE EPA REGISTRATION REVIEW PROCESS4 DOCKET OPENING FOCUS MEETING REGISTRATION REVIEW DECISION CASE DEVELOPMENT Summarizes the pesticide information and the review plan. Typically initiated with affected registrants and other stakeholders early in the process. EPA assesses changes in law/regulation since last review. EPA issues a draft decision with a 60-day comment period. It contains: Acts about the pesticide and its use The anticipated risk assessment and data needs An estimated review timeline. The preliminary workplan undergoes public consultation for 60 days after which a final workplan is published. If new assessment is needed, data gaps are identified and registrants asked for data call-in (DCI). Risk assessment or risk/benefit analysis is undertaken if needed. The public and regulatory partners are consulted. After this point, a final decision is issued on which the registrant must act. In some situations, interim decisions are issued before the final decision. This may require risk mitigation measures, call for new data, and outline schedules for subsequent data submission and review. The focus is to identify information needs and provide an opportunity to address areas of uncertainty affecting the risk assessment and risk management decisions. Although not mandatory, they are recommended.
  • 9. 9 PRESERVING LIFECYCLES The legislation concerning the placing of PPPs on the European single market is included in Regulation (EC) No. 1107/2009, with the specific data requirements for ASs and PPPs contained in Regulations (EU) No. 283/2013 and No. 284/2013. The authorization of ASs generally expires after ten years. To enable continued marketing and sales of PPPs, a renewal of authorization of the ASs must be sought. This renewal procedure is covered by Commission implementing Regulation (EU) No. 844/2012.5 and is a European-level process. Article 43 of Regulation (EC) No. 1107/2009 also provides the framework for the renewal of PPPs following the re-approval of an AS. This process is further elaborated on in a European Commission guidance document.6 The renewal of PPPs is the responsibility of the individual European Member States. EUROPEAN REGULATION RENEWAL PROGRAMS The programs for renewal of ASs in the EU are known as Annex I Renewal (AIR) programs. ASs are assigned to a program, group and/or batch, based on their expiration dates and level of priority, in order to manage and spread the workload of the renewal process. The AIR programs also assign each AS a ‘Rapporteur Member State’ (RMS) to undertake the task of evaluating the renewal application. The legislation concerning the placing of PPPs on the European single market is included in Regulation (EC) No. 1107/2009
  • 10. 10 PRESERVING LIFECYCLES THERE ARE FOUR AIR PROGRAMS, AS OUTLINED IN TABLE 1. TABLE 1: THE AIR PR GRAMS, AS OF FEBRUARY 2017 AS EXPIRY DATES NUMBER OF ASs REGULATION NOTES AIR1 7 (pilot project) EC NO. 737/2007 All substances were renewed for expiry on December 31, 2021, so they are due for second renewal under AIR4 and as such, are due for second renewal under AIR AIR2 2011–2012 31 EU NO. 1141/2010 29 renewal dossiers were submitted. It was necessary to extend the expiry dates for 23 of the ASs AIR3 January 1, 2013 – December 31, 2018 150 EU NO. 844/2012 EU NO. 1107/2009 Applications split into batches, with extensions for some to allow for sufficient time for dossier preparation by companies and/or balance workload in reviewing States AIR4 January 1, 2019 – December 31, 2021 214 EU NO. 844/2012 EU NO. 1107/2009 Prioritized into four groups (SANTE-2016-10616), Details of the latest updates for renewal programs, AIR3 and AIR4, can be found on the EC website
  • 11. 11 PRESERVING LIFECYCLES For the current AIR4 substances, applicants must apply for renewal three years before the expiry date of an approved AS. Article 17 of Regulation 1107/2009 allows for extensions to the expiry dates of ASs, where it would not be possible to take a decision before the current expiry date, for reasons beyond the control of the applicant. THE MAIN REASONS THESE EXTENSIONS ARE REQUIRED ARE: ▶▶ Delays in assessment ▶▶ Delays in decision-making – this is true for highly complex cases ▶▶ Facilitation of the review through the Member States by balancing capacity – this is the case for AIR4. TIMELINES AND EXTENSIONS
  • 12. 12 PRESERVING LIFECYCLES FIGURE 3: THE AIR RENEWAL PROCESS7 APPLICATION (36 months before expiry) SUBMISSION (30 months before expiry) RAR EVALUATION (RAR issued 12 months post submission) PEER REVIEW (Review 8 1/2 – 11 months) RENEWAL DECISION (~9 months duration) APPLICATION REVIEW Registrants submit an application containing limited information to indicate their intent of submitting a dossier to pursue active substance renewal. RMS conducts admissibility check. Registrant must respond within 14 days to calls for missing information. Registrants create and submit a renewal dossier. For most ASs, the dossier must be submitted 6 months post-application. For AIR4, some groups’ expiry dates have been extended by 1 to 3 years to allow more time for dossier submission. RMS conducts an initial review check; registrants must respond to any data requests within 14 days. A draft Renewal Assessment Report (RAR) is issued 12 months after dossier submission. Requests for additional information may be made. The RAR is passed to the European Food Safety Authority for publication and consultation. The final decision is made by a vote of the Standing Committee on the Food Chain and Animal Health. Renewal is officially adopted by the Commission and the results are published.
  • 13. 13 PRESERVING LIFECYCLES In the final section of this e-book, we will provide some practical advice to help companies tackle the renewal process. FORM A TASKFORCE OR CONSORTIUM A major difference between the application for marketing authorization of a new AS and that for renewal of an existing substance is that renewals are likely to involve more than one applicant and take the form of a joint submission. In fact, there is an expectation that stakeholders with an interest in the AS will reach agreement to cooperate in the re-approval process and submit a joint dossier. For joint submissions to work efficiently, it is important to establish a task force or consortium of all companies that have an interest in an AS used in specific PPPs. With many older chemicals out of patent, the list of interested companies could be large. By establishing a consortium, the division of the costs for dossier creation and submission can be shared within a clear legal framework. Once renewal is gained, all parties share the data, which can be used for the renewal of individual PPP registrations. STEPS TO ACHIEVE SUCCESSFUL ‘AS’ RENEWAL PLAN AHEAD AND START EARLY From experience, we know that you need to start well before the application date for an AS renewal. In the EU, where applications are required three years before the expiry date, however it is recommended to start the process at least two years before that – that is, five years before expiry. This gives sufficient time for the following important activities: ▶▶ Assess data gaps: it is essential to review the data available for the AS against the current data requirements and guidance, to identify what data are missing or suboptimal. Past experience and learning from substances that have already been, or are being, evaluated as part of earlier AIR submissions can also be taken into account.
  • 14. 14 PRESERVING LIFECYCLES ▶▶ Identify a costed plan for addressing gaps in data: once data gaps are established, the next step is creating a plan to address them. This plan should identify what studies could be defended and what new studies may need to be carried out. The challenge when consortia reach this stage is balancing the expenditure of new studies against the overall return from the AS. Having both regulatory and scientific expertise under one roof enhances decision-making and prioritization at this stage. ▶▶ Conduct studies: by starting two years before the application deadline for renewal, it is possible to conduct two seasons of field studies if required. ▶▶ Organize a pre-submission meeting with the RMS: this is the opportunity to have an open and frank discussion with the RMS about your AS, and the plans and strategy for renewal. It is important that particular areas of concern are discussed. Experience has shown these meetings are invaluable for both parties, with many questions answered. ▶▶ Prepare and submit the renewal application and updating statement: this should include a reference list detailing the new studies that are intended to be submitted in the supplementary renewal dossier. ▶▶ Prepare and submit the supplementary renewal dossier: the dossier should be written up to the appropriate standards and following the templates required. It is important to build a case that will resonate with regulatory reviewers, anticipating and answering their concerns. The dossier is prepared and submitted in CADDY format. ▶▶ Respond to RMS questions during their evaluation: the time for preparing responses is usually limited, and it is important to have a clear understanding what is being asked, so seek clarification if necessary. Try to answer as fully as possible. ▶▶ Comment on RAR: it is important to be prepared to respond to the RARs when they are issued a year after dossier submission. Review them objectively, and be prepared to defend studies and provide comprehensive answers to any questions.
  • 15. 15 PRESERVING LIFECYCLES Application (36 months before expiry) RAR (12 months after submission) Submission (30 months before expiry) -5 -4 -3 -2 -1 EXPIRY PROPOSED REGISTRANT ACTIVITY TIMEFRAME EU REGULATORY RENEWAL TIMEFRAME Renewal decision Pre-submission meeting (sometime before application) Defend dossier and respond to RAR Data gap analysis Prepareand submitdossier Study plan Conduct studies – allowing 2 seasons of field studies FIGURE 4: THE ROUTE THROUGH AS RENEWAL
  • 16. 16 PRESERVING LIFECYCLES Given the complexity of managing these long-term, regulatory renewals and study programs, it can be of great added value to work with a partner who has experience in all the stages of the process. WORK WITH AN EXPERIENCED PARTNER TRUSTED PARTNERS CAN PROVIDE NUMEROUS ADVANTAGES THROUGHOUT THE RENEWAL PROCESS, INCLUDING: ▶▶ Wide experience covering multiple AS chemistries and activities ▶▶ A consultancy team with a background in industry, authorities, Contract Research Organizations (CROs) and other consulting companies ▶▶ Thorough understanding of the crop protection market ▶▶ Strategic focus and industry perspective ▶▶ Experience and proven track record ▶▶ Flexible approach and close partnership ▶▶ Detailed planning and project management ▶▶ Timely communication It is important to remember that once the AS has been re-authorized, the process of product renewal begins, following the procedures laid down in Article 43.
  • 17. 17 PRESERVING LIFECYCLES ▶▶ Literature review: A comprehensive literature search, that meets the criteria in the EFSA Guidance (is required.8-11 A tiered approach is taken in order to identify those papers that are both relevant and reliable, and therefore merit inclusion and consideration of the results in the renewal dossier. ▶▶ Harmonized classification and labeling (CLH) of ASs is the responsibility of the European Chemicals Agency (ECHA). This requires preparation of dossiers (including IUCLID technical dossiers) for CLH under Regulation (EC) No. 1272/2008 (CLP Regulation), preparation of expert statements on technical and scientific issues regarding toxicity of ASs and supporting clients at ECHA risk assessment committee meetings. OTHER IMPORTANT ELEMENTS OF EU ‘AS’ REVIEW ▶▶ Maximum residue levels (MRLs): It is important to have appropriate MRLs (and/or import tolerances [ITs]) in place for all uses, not just the representative uses included in the renewal dossier. MRL application and setting is covered by Regulation (EC) No. 396/2005.10
  • 18. 18 PRESERVING LIFECYCLES The renewal process in the EU for existing ASs requires advance planning and careful, attentive management. SUMMARY FOUR KEY PIECES OF ADVICE ARE: ▶▶ Start early and plan ahead: do not leave planning for your renewal to the last minute. You need to start planning at least five years before the AS expiry date to give you time to establish, if necessary, a task force or consortium and agree your strategy, budget working practices and study program for the renewal process. ▶▶ Communicate clearly and work collaboratively with others: effective working partnerships with other stakeholders, such as task force members, consultants and CROs, requires good communication and clear agreement of roles and responsibilities. Engage with the renewing authority early to establish possible issues and scope. ▶▶ Be bold but realistic: review the data for your AS and characterize data gaps comprehensively; however, do not be afraid to look at your existing studies and plan a robust defense of them, while always having a contingency. ▶▶ Remember this is an ongoing process: renewal of approval is only a step towards meeting your commercial objectives, and the next stage of renewal of products, introduction of new products and extensions of use of existing products are just as important and require careful planning and management.
  • 19. 19 PRESERVING LIFECYCLES 1 Aspinal A. Pesticide usage in the United States: Trends During the 20th Century. Center for Integrated Pest Management. CIPM Technical Bulletin 2003; 105. 2 Mordor Intelligence. Crop protection chemicals (Pesticides) Market - Global Industry Growth, Trends and Forecasts (2017 - 2022). Published February 2017. www.mordorintelligence.com/industry- reports/global-crop-protection-chemicals- pesticides-market-industry 3 Reuters. BRIEF-Dow to divest portion of its corn hybrid seed business in Brazil to CITIC Agri Fund for $1.1 bln. July 11, 2017 http://uk.reuters.com/article/ brief-dow-to-divest-portion-of-its-corn- idUKASA09WQR 4 United States Environmental Protection Agency. Registration Review Process. www.epa.gov/pesticide-reevaluation/ registration-review-process REFERENCES 5 EFSA. Applications helpdesk – Renewal of approval under AIR programme: application procedure. www.efsa.europa. eu/sites/default/files/applications/ RenewalApprovalActSubPro.pdf 6 European Commission. SANCO/2010/13170 rev. 14. Guidance Document on the Renewal of Authorizations according to Article 43 of Regulation (EC) No 1107/2009. 2016. October 7, 2016. https://ec.europa.eu/ food/sites/food/files/plant/ docs/pesticides_aas_guidance_ renewal_1107-2009.pdf 7 1107 Vademecum, Fourth Edition, Pappas & Associates, Brussels, 2017 8 EFSA. Submission of scientific peer- reviewed open literature for the approval of pesticide active substances under Regulation (EC) No 1107/2009. EFSA Journal 2011; 9(2): 2092. https://efsa. onlinelibrary.wiley.com/doi/epdf/ 10.2903/j.efsa.2011.2092 9 European Union. Regulation (EC) No. 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directive 79/117/EEC and 91/414/EEC. Official Journal of the European Union L 309, November 24, 2009. https://eur-lex. europa.eu/legal-content/EN/TXT/ PDF/?uri=OJ:L:2009:309:FULL&from=EN 10 European Parliament, Council of the European Union. Regulation (EC) No. 396/2005 of the European Parliament and of the Council of 23 February 2005 on maximum residue levels of pesticides in or on food and feed of plant and animal origin and amending Council Directive 91/414/ EEC. Official Journal of the European Union L 70, March 16, 2005. https://eur-lex. europa.eu/legal-content/EN/TXT/ PDF/?uri=OJ:L:2005:070:FULL&from=EN 11 European Commission. Renewal of approval. https://ec.europa.eu/food/ plant/pesticides/approval_active_ substances/approval_renewal_en
  • 20. 20 PRESERVING LIFECYCLES AIR Annex I Renewal AS Active substance CLH Harmonized classification and labeling CLP Classification, Labeling and Packaging CRO Contract research organization DCI Data call-in EFSA European Food Safety Authority EPA Environment Protection Agency EU European Union FIFRA Federal Insecticide, Fungicide, and Rodenticide Act TERMINOLOGY IT Import tolerance MRL Maximum residue level PPP Plant protection product – a term often used interchangeably with the term pesticide; however, pesticide is broader and also covers non-plant or crop use (for example, biocides) RAR Renewal Assessment Report RMS Rapporteur Member State – the member state of the EU that acts as the lead reviewer of renewal dossiers TGAI Technical-grade active ingredient
  • 21. 21 PRESERVING LIFECYCLES Learn more about our crop protection solutions at www.covance.com/crop-protection Covance is the drug, medical device and diagnostics business segment of LabCorp, a leading global life sciences company. COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world. The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440 Europe/Africa +00.800.2682.2682 +44.1423.500888 Asia Pacific +800.6568.3000 +65.6.5686588 © Copyright 2019 Covance Inc. EBKCPC001-0819